GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc.

GEHC

Rank in Stocks #766
GE HealthCare Technologies Inc. is a global medical technology company that... GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Share Price
$70.09
Market Cap
$31.66B
Change (1 day)
0.47%
Change (1 year)
-7.15%
Country
US
Trade GE HealthCare Technologies Inc. (GEHC)

Category

Healthcare
P/E ratio for GE HealthCare Technologies Inc. (GEHC)
P/E ratio as of October 2026 TTM: 19.68
According to GE HealthCare Technologies Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.68. At the end of 2024 the company had a P/E ratio of 17.89.
P/E ratio history for GE HealthCare Technologies Inc. from 2019 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 19.68 -11.73%
2025 22.29 24.60%
2024 17.89 -20.27%
2023 22.44 62.22%
2022 13.83 13.91%
2021 12.14 516.21%
2020 1.97 -88.99%
2019 17.90 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
64.40 227.32%
AU
44.30 125.16%
US
-47.78 -342.82%
US
-123.90 -729.71%
US
- -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.